Plain-English translation of NCT06102785 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a Phase II clinical trial testing a combination of two oral medications—Fruquintinib and TAS-102—for people with advanced stomach cancer. Both drugs are pills you take by mouth, which means you avoid frequent hospital visits. Researchers want to see if this combination works better for stomach cancer than it might for other cancers.
Doctors already know this medication combination may help some cancer patients, but it hasn't been thoroughly tested in people with stomach cancer. This trial will show whether this treatment is effective and safe for your specific type of cancer.
You likely qualify if…
You likely don't qualify if…
You would take two oral medications on a repeating 4-week schedule: Fruquintinib as a daily pill for 3 weeks, then 1 week off; and TAS-102 twice daily for specific days within each cycle. You'll have regular clinic visits and blood tests to monitor how well the treatment is working and check for any side effects. The study involves about 30 people total, and you would be expected to follow the treatment plan closely and report any changes in how you feel.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~30 participants
Started
November 2023
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Deng, MD
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.